Deinove S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALDEI.PA research report →
About the company
Headquartered in Grabels, France, DEINOVE SA is a biotechnology company founded in 2006. The company focuses on the discovery, development, and production of innovative compounds derived from microorganisms, catering to the global health, nutrition, and cosmetics industries. Among its key developments is DNV3837, an antibiotic currently undergoing Phase II clinical trials for the treatment of Clostridioides difficile infections.
- CEO
- Alexis Rideau
- IPO
- 2010
- Employees
- 44
- HQ
- Grabels, FR
- Market Cap
- $1.13M
- P/E
- -0.11
- P/S
- 3.09
- P/B
- -0.06
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
- Gross Margin
- -904.09%
- Op Margin
- -1997.55%
- Net Margin
- -1904.90%
- ROE
- 60.55%
- ROIC
- -97.26%
- Revenue
- $367.00K · 13.62%
- Net Income
- $-6,991,000 · -2.93%
- EPS
- $-0.24 · 14.29%
- Op Income
- $-7,331,000
- FCF YoY
- -26.66%
- 52W High
- $0.44
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.11
- Beta
- 0.79
- Avg Volume
- 5.99M
Get TickerSpark's AI analysis on ALDEI.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALDEI.PA coverage
Recent articles, reports, and earnings notes.
No research on ALDEI.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALDEI.PA report →Similar companies
Peers in the same neighborhood.